ALTITUDE-AD: Use of a Validated Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease (S15.008)
Year: 2025
Type: article
Source: Neurology
Authors: H Todd Feaster, Karen Sundell, Maddelyn Hyland, Gopalan Sethuraman, Vladimir Skljarevski, June Kaplow, Robert A. Dean, Jasna Jerecic, Eric Siemers
Institution: Acumen Pharmaceuticals (United States)
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409237198